SCHEMBL5359077

SCHEMBL5359077

Cc1ccc(C=C2C(=O)Nc3ccc(CO)cc32)s1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 1/20 0.47
ALDH1A1 P00352 7/20 0.47
MAPT P10636 7/20 0.47
KMT2A Q03164 7/20 0.47
HPGD P15428 4/20 0.47
MEN1 O00255 4/20 0.47
NPSR1 Q6W5P4 2/20 0.44
TDP1 Q9NUW8 2/20 0.44
THRB P10828 1/20 0.44
RECQL P46063 1/20 0.44
PDPK1 O15530 5/20 0.43
KDR P35968 2/20 0.42
S1PR4 O95977 1/20 0.42
HSP90AA1 P07900 1/20 0.42
ALOX12 P18054 1/20 0.42
S1PR1 P21453 1/20 0.42
NTSR1 P30989 1/20 0.42
HTT P42858 1/20 0.42
LRRK2 Q5S007 1/20 0.41
POLB P06746 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5367195 0.88 PDPK1 (0.57) EGFRALDH1A1MAPTKMT2AHPGD
SCHEMBL5362113 0.86 KMT2A (0.47) EGFRALDH1A1MAPTKMT2AHPGD
SCHEMBL14519107 0.85 FGFR1 (0.48) EGFRALDH1A1MAPTKMT2AHPGD
SCHEMBL6001533 0.81 LRRK2 (0.58) EGFRLRRK2
SCHEMBL6001532 0.81 LRRK2 (0.58) EGFRLRRK2
SCHEMBL14519109 0.81 TLK2 (0.57) KMT2AMEN1PDPK1KDR
SCHEMBL5358237 0.80 LRRK2 (0.44) EGFRMAPTNPSR1PDPK1KDR
SCHEMBL5364974 0.79 PDPK1 (0.46) EGFRALDH1A1MAPTKMT2AHPGD
SCHEMBL5365829 0.78 PDPK1 (0.48) EGFRPDPK1KDR
SCHEMBL5368073 0.78 PDPK1 (0.61) PDPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7202265-B2 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. (US) 2007-04-10 US disclosed
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. 2005-09-08 US disclosed
EP-1247803-A2 Indolinone compounds suitable for modulation of protein kinases Sugen, Inc. (US) 2002-10-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease FRK, PTK2, DSTYK EGFR 286/4885ALDH1A1 2044/4885MAPT 3048/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.